By Andrew Nichols, Tungsten Analytics lead and head of procurement
Cost control has never been higher on the agenda. Accounts teams in pharmaceutical businesses are well acquainted with the need to spend hours completing detailed analysis of extensive data, but what they might not know is that there is an alternative: artificial intelligence.
Machine learning has now become a useful tool for tackling cost analysis. Here at Tungsten we are interested in exploring this further, looking at how businesses can be better informed about procurement options using the latest developments in technology.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze